34 results about "Cells progenitors" patented technology

A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and / or albumin and / or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations.

The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.

The invention pertains to methods and devices for the in vitro culture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors. The hematopoietic progenitor cells are cultured in the absence of exogenously added hematopoietic growth factors without loss in cell progenitor cell numbers and / or functionality, while maintaining progenitor cell pluripotency.

A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and / or albumin and / or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations.

The present disclosure relates to a novel hepatocyte-like cell progenitor and / or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in, e.g., pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. In particular is presented a definitive endoderm derived hepatocyte-like cell with important liver-expressed marker genes and important metabolizing enzymes, as well as drug transporters.

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte / erythroid progenitor cells (MEP) and granulocyte / monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid / megakaryocytic or myelomonocytic lineages. Tηεχελλενιχημεντμετηoδσεμπλoψεαγεντστηατσπεχαλλψεψoγνιζε Tηψ-1; ανδIΛ-7 Pα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors / erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS β-globin promoter / enhancer. Such transduced SS erythroid cells differentiate into mature SSRBCs that exhibit sustained synthesis and expression of SS hemoglobin, a tumoricidal protein(s). Both mature and progenitor SS-cells carrying tumoricidal transgene(s) are capable of selectively localizing in tumor microenvironment, occluding tumor microvessels and inducing a tumoricidal response.

The present disclosure relates to making a hybrid pig-human thymic tissue and using the hybrid thymic tissue to induce tolerance in xenotransplantation. The hybrid thymic tissue can also be used for restoring or inducing immunocompetence in a recipient as well as restoring or promoting the thymus-dependent ability for T cell progenitors to develop into mature functional T cells in a recipient.

The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.

The present invention relates to methods for generating mature insulin-producing β-like cells comprising the steps: (a) isolating, purifying and / or enriching β-cell progenitor cells from a population of cells; (b) differentiation of the β-cell progenitor cells into immature insulin-producing β-like cells; and (c) maturation of the immature insulin-producing β-like cells into mature insulin-producing β-like cells, comprising exposing the immature insulin-producing β-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing β-like cells for use in treating diabetes.

The invention discloses a culture method of vascular endothelial progenitor cells, which comprises the following steps: 1) inducing differentiation of multipotent stem cells in a culture medium A to form mesendoderm precursor cells; and 2) inducing differentiation of the mesendoderm precursor cells in a culture medium B to form the vascular endothelial progenitor cells. The culture medium A contains a DMEM (dulbecco's modified eagle medium) culture medium, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, activin A, a bone formation protein 4 and a glycogen synthetase kinase-3 inhibitor. The culture medium B contains a DMEM culture medium, an F12 culture medium, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signal pathway inhibitor. The culture media used in the culture method do not contain any animal-derived component, and can provide sufficient nutrient substances and stable living environments for the cultured cells, thereby efficiently inducing the differentiation of the human multipotent stem cells to form the vascular-grid vascular endothelial progenitor cells which are highly similar to the human cord vessel endothelial cells.

The present invention refers to cells from a subpopulation of progenitors of endothelial cells loaded with gold nanoparticles sensitive to excitation with infrared radiation with consequent release ofthermal energy, to a composition comprising a plurality of these cells and to their use in the diagnosis and treatment of solid tumours thanks to the selective localization of the composition in thetumour mass, which can be thus identified easily for diagnostic purposes by marking the cells with appropriate marking agents, or treated by stimulation with pulsed laser beam up to the complete cauterization of the tumour mass for a targeted and highly effective therapeutic action.

The invention relates to a preparation method of a functional coating material for biological tissue scaffolds or catheters. The preparation method comprises the following steps of: self-assembling PEG-grafted chitosan with one or more functional compounds and growth factors in a solution state The functional composite material solution is obtained, and the functional coating material is obtained by cross-linking treatment after coating the substrate; the substrate is a biological tissue scaffold or a catheter; and the functional compound is a compound with a sulfonic acid group. The functional coating material prepared by the preparation method of the present invention can regulate the antithrombotic performance of the vascular stent, and at the same time, the functional compounds / growth factors can also induce the stem cells, endothelial cells / progenitor cells in the blood to aggregate on the material, accelerate the endothelialization.

The invention belongs to the field of culture medium, and in particular relates to a serum-free culture medium for erythrocyte progenitor cells, including basal culture medium and other additive components; the other additive components include ITS additive, GlutaMAX, Lipid Concentrate, L-ascorbic acid 2-phosphorylated hemi Magnesium salt hydrate, inorganic salts, lipoic acid, hydrocortisone, stem cell factor, erythropoietin, and interleukin-3. The beneficial effects of the present invention are: the composition of the whole medium system is clear, the quality is stable, and the erythrocyte progenitor cells in the blood cells are selectively amplified, so that the erythrocyte progenitor cells can effectively express specificity on the basis of maintaining their original stemness characteristics CD71+ / CD235a+ / – is a marker, and the ratio of CD71+ / CD235a+ / – accounts for about 50% to 100%. The culture medium of the present invention is suitable for clinical application and scientific research.

The invention discloses a method for promoting the healing of diabetic wounds by using hFDSPCs-CM and HA, combining the conditioned medium of dermal stem cells derived from foreskin and hyaluronic acid to promote the healing of diabetic wounds, and for the first time the dermal stem cells / progenitor cells derived from The conditioned medium combined with hyaluronic acid is applied to the diabetic mouse model. Compared with the currently widely used conditioned medium of adipose-derived stem cells, it has a better effect of promoting wound healing, especially in promoting collagen synthesis. Diabetic refractory wounds are of great significance, and the simple operation is expected to achieve clinical transformation in the future. The present invention provides relevant data that the conditioned medium of the foreskin-derived dermal stem / progenitor cells promotes the healing of diabetic wounds, and explores the relevant mechanism in in vivo and in vitro experiments.

The present disclosure relates generally to biomaterial implants and methods for delivering a cell to an individual in need thereof and, more particularly, to biomaterial implants and techniques for delivering islets and / or β-cell progenitors to an individual.

The present application discloses a method of treating pancreatitis by administering to the patient mesenchymal stem cells that are obtained by manipulating a biological sample of cells, which includes multi-lineage stem cells, progenitor cells, other marrow stromal cells: allowing the sample of cells to settle in a container; transferring supernatant from the container to another container; and isolating cells from the supernatant, which has comparatively lower density in the sample.